If approved, epcoritamab (TEPKINLY®) will become the first and only subcutaneous bispecific antibody conditionally approved as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) DLBCL after two or more lines of systemic therapy The positive CHMP opinion is…